In last trading session, Olema Pharmaceuticals Inc (NASDAQ:OLMA) saw 0.51 million shares changing hands with its beta currently measuring 2.06. Company’s recent per share price level of $4.99 trading at -$0.09 or -1.77% at ring of the bell on the day assigns it a market valuation of $340.98M. That closing price of OLMA’s stock is at a discount of -233.07% from its 52-week high price of $16.62 and is indicating a premium of 7.82% from its 52-week low price of $4.60.
For Olema Pharmaceuticals Inc (OLMA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0.17 in the current quarter.
Olema Pharmaceuticals Inc (NASDAQ:OLMA) trade information
Upright in the red during last session for losing -1.77%, in the last five days OLMA remained trading in the green while hitting it’s week-highest on Tuesday, 02/18/25 when the stock touched $4.99 price level, adding 6.55% to its value on the day. Olema Pharmaceuticals Inc’s shares saw a change of -14.41% in year-to-date performance and have moved 3.31% in past 5-day. Olema Pharmaceuticals Inc (NASDAQ:OLMA) showed a performance of -12.15% in past 30-days.
Wall Street analysts have assigned a consensus price target of 27 to the stock, which implies a rise of 81.52% to its current value. Analysts have been projecting 27 as a low price target for the stock while placing it at a high target of 27. It follows that stock’s current price would drop -441.08% in reaching the projected high whereas dropping to the targeted low would mean a loss of -441.08% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -105.28% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -7.49% while estimates for its earnings growth in next 5 years are of -13.34%.
Olema Pharmaceuticals Inc (NASDAQ:OLMA)’s Major holders
BVF INC/IL is the top institutional holder at OLMA for having 9.14 million shares of worth $98.85 million. And as of 2024-06-30, it was holding 16.2322 of the company’s outstanding shares.
The second largest institutional holder is PARADIGM BIOCAPITAL ADVISORS LP, which was holding about 7.9 million shares on 2024-06-30. The number of shares represents firm’s hold over 14.0428 of outstanding shares, having a total worth of $85.52 million.
On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 1.49 shares of worth $7.42 million or 2.00% of the total outstanding shares. The later fund manager was in possession of 1.11 shares on Nov 30, 2024 , making its stake of worth around $5.52 million in the company or a holder of 1.49% of company’s stock.
